Alterations of monocyte NF-κB p65/RelA signaling in a cohort of older medical patients, age-matched controls, and healthy young adults

Table 2 Linear regressions for the associations of monocyte basal pNF-κB MFI with plasma biomarkers and aging measures in the Patient Group at 30-day follow-up and Older Controls

	Patient Group at 30-day follow-up			Older Controls
	Estimate (β)	95% CI	P-value	Estimate (β)	95% CI	P-value
Plasma biomarkers
suPAR (ng/mL) ^a	1.48	(− 3.0–6.1)	0.51	3.16	(− 0.5–7.0)	0.09
CRP (mg/L) ^a	5.96	(−7.3–21.2)	0.39	7.62	(− 6.0–23.3)	0.28
IL-6 (pg/mL) ^a	3.92	(−4.4–13.0)	0.36	10.64	(0.4–21.9)	0.04
IL-18 (pg/mL) ^a	3.46	(−2.9–10.2)	0.29	3.08	(− 3.5–10.1)	0.36
TNF-α (pg/mL) ^a	2.72	(−3.3–9.1)	0.37	4.85	(1.4–8.5)	0.007
GDF15 (pg/mL) ^a	2.97	(−2.9–9.1)	0.32	1.67	(− 2.8–6.3)	0.46
Frailty
FI-OutRef	−0.05	(− 0.3–0.2)	0.71	0.24	(0.1–0.4)	0.005
Physical function
4-m gait speed (m/s)	0.01	(−0.0–0.0)	0.35	0.00	(0.0–0.0)	0.80
Hand grip strength (kg)	− 0.02	(− 1.3–1.3)	0.97	−1.17	(− 2.5–0.2)	0.08
Chair stand test (repetitions)	0.29	(−0.2–0.8)	0.23	−0.30	(− 0.8–0.2)	0.23
Cognitive function
MMSE (points)	−0.03	(− 0.3–0.2)	0.82	−0.19	(− 0.4–0.1)	0.16
Trail making test A (seconds)	−1.44	(− 6.2–3.5)	0.55	2.79	(−3.3–9.2)	0.37
Trail making test B (seconds)	−1.24	(− 6.9–4.8)	0.67	3.82	(− 3.0–11.1)	0.27

^a Variables were log-transformed, and estimates represent percent change in dependent variable per 10% increment in pNF-κB MFI
Abbreviations: CRP C-reactive protein, FI-OutRef Frailty index OutRef, GDF15 growth differentiation factor 15, IL interleukin, MMSE Mini Mental State Examination, suPAR soluble urokinase plasminogen activator receptor, TNF-α tumor necrosis factor alpha

ISSN: 1742-4933